VERMILLION INCORPORATED (NASD: VRML)
"Up 75.93% on Monday"

Detailed Quote: http://www.otcpicks.com/quotes/VRML.php

Vermillion, Inc. discovers, develops, and commercializes diagnostic tests that help physicians to diagnose and treat patients. It develops clinical protein biomarker diagnostic products and services in the fields of oncology, hematology, cardiology, and women's health with initial focus on ovarian cancer. The company has collaborations with various academic and research institutions, including The Johns Hopkins University School of Medicine focusing on oncology, primarily breast, prostate, and ovarian cancers; The University of Texas M.D. Anderson Cancer Center that focuses on cancers of the reproductive tract, including the uterus, fallopian tubes, and ovaries; and The University of Texas Medical Branch for the discovery and development of new products for personalized or targeted medicine, primarily in the field of liver disease. It also has collaboration agreements with The Katholieke Universiteit Leuven for the discovery, validation, and characterization of biomarkers related to gynecological diseases; Ohio State University Research Foundation for the discovery, validation, and characterization of biomarkers related to thrombotic thrombocytopenic purpura, and production of associated technology; Stanford University for the discovery, validation, and characterization of biomarkers related to cardiovascular diseases, primarily peripheral arterial disease; and Clinic of Gynecology and Clinic of Oncology, Rigshospitalet, Copenhagen University Hospital. In addition, Vermillion has strategic alliance with Quest Diagnostics Incorporated for commercializing up to three diagnostic tests. The company was founded as Abiotic Systems in 1993 and changed its name to Ciphergen Biosystems, Inc. in 1995. It further changed its name to Vermillion, Inc. in 2007. The company is based in Fremont, California.

VRML News:

May 1 - Vermillion's Roundtable Teleconference Highlights Peripheral Artery Disease Diagnostic Program; Features Commentary from Vascular Medicine Expert

Company Offers Access to Archived Web Cast and Phone Replay of the Forum

Vermillion, Inc. (NASD: VRML), a molecular diagnostics company, recently held a roundtable teleconference focusing on its peripheral artery disease (PAD) diagnostic program and the need for improved detection of this life- and limb-threatening condition. The teleconference, which took place yesterday, featured keynote speaker John Cooke, M.D., Ph.D., Professor of Medicine at Stanford University, whose research forms the basis of Vermillion's PAD blood test.

The roundtable discussion was the first of a series of calls to provide investors an opportunity to hear more about Vermillion's diagnostic programs and understand the various markets that the company seeks to address. Yesterday's forum served as a means to educate this audience about the current state of PAD and why there is a clinical need for a blood test that can determine a person's risk of developing the disease. PAD, a serious condition affecting some eight to 12 million Americans, can double a person's risk of heart attack and stroke, and increase the risk of amputation and death. There are treatments that can save the lives and limbs of these patients once the disease is recognized.

"The signs and symptoms of PAD often go unnoticed, and as a result many patients are not being properly diagnosed. We are in serious need of new, innovative tools to aid in the diagnosis and management of this life- threatening condition," said Dr. Cooke. "Together with Vermillion, we are working to develop a simple blood test that will stratify an individual's risk of developing PAD. This will serve as an important advancement in the overall management of the disease - benefiting both the patient and the physician alike."

"Improving diagnosis of PAD, expediting treatment and enhancing patient outcomes is a key goal for Vermillion, as well as for Dr. Cooke and his research team at Stanford," said Gail Page, President and CEO of Vermillion. "We believe that our PAD diagnostic program will achieve these goals, and look forward to reporting additional clinical and commercial results in the coming months."

To access the archived Web cast of the conference call, visit the Investor Relations section of Vermillion's Web site at www.vermillion.com. Additionally, a telephone replay of the roundtable discussion is available through May 30, and may be accessed by dialing (800) 633-8284 from the United States and Canada or (+1 402) 977-9140 internationally. The replay pass code is 21381902.

ABOUT VERMILLION'S PAD DIAGNOSTIC TEST PROGRAM

In collaboration with Dr. Cooke and his research team at Stanford University, Vermillion has developed a novel panel of biomarkers in an effort to determine the risk of PAD through a simple blood test. The company has an exclusive license agreement with Stanford to develop and commercialize this panel.

CYCLONE POWER TECHNOLOGIES (OTC: CYPW)
"Up 71.43% on Monday"

Detailed Quote: http://www.otcpicks.com/quotes/CYPW.php

Cyclone holds the U.S. patent, international patent applications, and exclusive commercial rights to the Cyclone Engine, an environmentally friendly and highly efficient external combustion, heat-regenerative engine. Developed by Cyclone's President and CEO, Harry Schoell, the Cyclone Engine regenerates (or recycles) its heat, which allows it to run cleaner, cooler and more efficiently than traditional internal combustion engines. The Cyclone Engine is capable of running on any liquid or gaseous fuel, including ethanol, bio-diesel and propane. The company also recently filed a patent application for its Waste Heat Engine, a low-pressure engine capable of running on heat emitted from external sources, including the waste exhaust of a power generator or renewable solar power. Both these engines are lubricated with de-ionized water instead of motor oil, and by eliminating many subsystems like oil pumps, radiators, catalytic converters and fuel injectors, the Cyclone Engines are expected to cost less to manufacture, operate and maintain. The Cyclone Engine is highly scalable and sufficiently powerful for applications ranging from lawn equipment and small home generators, large stand-alone generators, to cars, trucks, buses, RV's, boats and ships, as well as earth moving equipment and locomotives.

CYPW News:

May 1 - Cyclone Power Technologies Named Environmental Business of the Year

The Environmental Protection Department of Broward County, Florida has named Cyclone Power Technologies, Inc. (OTC: CYPW) the Environmental Business of the Year.

The announcement was made Tuesday at the presentation ceremony for the county's Emerald Awards, recognizing the achievements of local businesses in protecting and preserving the environment. Cyclone was chosen as Environmental Business of the Year over twelve Emerald Award winners and dozens of other locally recognized companies.

In naming Cyclone for its highest honor, the Broward EPD considered the positive impact that Cyclone's technology could have on the environment. The company calculated that if only 10 percent of lawn mowers in the state of Florida were switched to a Cyclone Engine, consumers would conserve annually over 12 million gallons of gasoline and reduce ground spillage of gas and motor oil by an estimated 100,000 gallons. Additionally, each year our air could be spared over 127,200 pounds of hydrocarbons, 1,200 pounds of nitrogen oxides, and 3,360 pounds of irritating particles; and over 1 million pounds of carbon dioxide could be offset by using carbon-neutral bio-fuels.

"We are working hard to bring the Cyclone engine to the public, as we know its impact on creating a healthier environment will be enormous," stated Harry Schoell, CEO of Cyclone. "We are so pleased that our technology has been recognized and elevated by our local environmental protection department."

The company anticipates the first of its engines will be commercially viable by 2009, and believes that walk-behind lawn mower applications could be available to consumers late next year. The company is also developing and bench testing engines for use in portable generators, riding mowers, off-road equipment, automobiles, trucks, busses, locomotives and ships.

BIO-MATRIX SCIENTIFIC GROUP (OTCBB: BMSN)
"Up 50.00% on Monday"

Detailed Quote: http://www.otcpicks.com/quotes/BMSN.php

Bio-Matrix Scientific Group, Inc., a development stage company, engages in the design, development, and marketing of medical devices, specifically disposable instruments used in stem cell extraction and tissue transfer procedures. It has developed approximately 192 disposable instruments for use in the plastic surgery field and stem cell research. The instruments are designed to be used to harvest adult stem cells from adipose (fat) tissue. Its products primarily include cannula, tissue transfer cannula and connectors, syringe clip, cannula handle and storage system. The company seeks to market and sell these instruments to plastic surgeons. Bio-Matrix Scientific Group is also constructing a cryogenic cellular storage facility and specifically stem cell banking facility. The company was founded in 2005 and is based in San Diego, California.

BMSN News:

May 5 - Bio-Matrix Scientific Group, Inc. Submits Application and Quality Systems Documentation to the State of California for Tissue Bank License

Bio-Matrix Scientific Group Inc. (OTCBB: BMSN), a biotechnology company focused on adult stem cell processing and cryogenic storage, announced that on April 24, 2008 it submitted for review all required documentation (including copies of its Quality Systems Operating Procedures) to the California Health and Human Services Agency in connection with an application to acquire a Tissue Bank License in the State of California.

The State of California requires human cell, tissue, cellular and tissue-based product facilities to follow the current Good Tissue Practice (GTP) standards, which govern the methods used in, and the facilities and controls used for, the manufacture and processing of human tissue, cellular and tissue-based products.

The Company has already been granted a Biologics License which allows the Company to cryogenically store blood related specimens at its California facility and its registration as a cellular and tissue-based product facility has been accepted by the FDA. The FDA requires human cells, tissue, cellular and tissue-based product facilities to register with the agency and list their human cells, tissues, and cellular and tissue-based products (HCT/Ps).

The granting of a Tissue Bank License by the California Health and Human Services Agency would allow the Company to process and store stem cells from adipose tissue (fat), cord blood and peripheral blood.

BUDGET WASTE INCORPORATED (OTC: BDGW)
"Up 35.71% on Monday"

Detailed Quote: http://www.otcpicks.com/quotes/BDGW.php

Budget Waste Inc. is a waste solutions company in Western Canada providing complete waste and recycling services to commercial, industrial, construction, homebuilding, oilfield and residential clients. With its broad range of innovative services, the company offers its customers more value for their dollar and reduces accounting costs by providing streamlined billing. BWI is currently following its growth-through-acquisition strategy with exceptional success. With regulations throughout North America pressing companies and individuals to be more vigilant in the way they handle their waste products, company officials see vast opportunity for expansion of BWI's distinctive services.

BDGW News:

May 5 - Budget Waste Inc. Awarded $11,200,000 Recycling and Waste Contract

Budget Waste Inc. (OTC: BDGW), a leading provider of waste and recycling services to industrial, residential, and commercial clients, announced the following contract information.

Budget Waste has been awarded the exclusive rights to be the supplier of choice for waste bins, sorting and recycling in Mahogany, a community developed and managed by Hopewell Residential Communities Inc. Mahogany is a 12 to 15 year project that will, upon completion, yield 8000 single and multi family homes within the City of Calgary. Budget Waste has provided waste, sorting and recycling services for Hopewell Residential Communities Inc. in the development of Copperfield for the past 6 years. The recycling program for Mahogany has an estimated contract value of $11,200,000.00 over the development term of the project. The terms and conditions of the contract will be reviewed yearly in November.

Hopewell has been recognized by Calgary Region Home Builders Association five times as Developer of the Year for their distinctive award winning communities in Alberta.

Hopewell's Corporate Mission

We are a successful land development company of empowered team members, achieving performance goals through operational excellence and well-planned strategic growth.

OCCULOGIX INCORPORATED (NASD: OCCX)
"Up 46.18% on Monday"

Detailed Quote: http://www.otcpicks.com/quotes/OCCX.php

OccuLogix, Inc., an ophthalmic therapeutic company, provides treatments for eye diseases. Its treatments primarily include age-related macular degeneration and glaucoma. The company develops RHEO System, which consists of the OctoNova Pump and a disposable treatment set, is designed to improve microcirculation in the eye by filtering high molecular weight proteins and other macromolecules from the patient's plasma. OccuLogix operates in the United States, Canada, Europe, and Israel. The company was founded in 1996 and is headquartered in Mississauga, Canada.

OCCX News:

May 5 - OccuLogix Secures Additional Bridge Loan

OccuLogix, Inc. (NASD: OCCX) (Toronto: OC.TO) announced that it has secured a bridge loan in an aggregate principal amount of U.S.$300,000 from a number of private parties (the "Additional Bridge Loan"). The Additional Bridge Loan constitutes an increase to the principal amount of the U.S.$3,000,000 principal amount bridge loan that the Company announced on February 19, 2008 (the "Original Bridge Loan") and was advanced on substantially the same terms and conditions as the Original Bridge Loan, pursuant to an amendment of the loan agreement for the Original Bridge Loan.

The proceeds of the Additional Bridge Loan will be used for general corporate purposes. The Company expects that such proceeds will be sufficient to sustain the Company's operations until the closing of OccuLogix's acquisition of the minority interest in San Diego-based OcuSense, Inc. ("OcuSense") that it does not already own, by way of a merger, and the closing of the proposed private placement of up to U.S.$6,500,000 of the Company's common stock. Both of these transactions had been announced on April 22, 2008. The securities to be offered in the OcuSense merger transaction and the proposed private placement have not been registered under the Securities Act of 1933, as amended (the "Act") or any state securities laws or qualified under any Canadian provincial or territorial securities laws, and may not be offered or sold in the United States absent registration, or an applicable exemption from registration, under the Act and applicable state securities laws or in Canada absent a valid prospectus, or an applicable exemption from the prospectus requirements, under applicable provincial and territorial securities laws.

The Additional Bridge Loan bears interest at a rate of 12% per annum and will have the same maturity date as the Original Bridge Loan. Like the repayment of the Original Bridge Loan, the repayment of the Additional Bridge Loan is secured by a pledge by the Company of its currently held 50.1% ownership interest (on a fully diluted basis) in OcuSense.

Under the terms of the loan agreement for the Original Bridge Loan, the Company has two pre-payment options available to it, should it decide to not wait until the maturity date to repay the loan. Under the first pre-payment option, the Company may repay the Original Bridge Loan in full by paying the lenders, in cash, the amount of outstanding principal and accrued interest and issuing to the lenders five-year warrants in an aggregate amount equal to approximately 19.9% of the issued and outstanding shares of the Company's common stock (but not to exceed 20% of the issued and outstanding shares of the Company's common stock). The warrants would be exercisable into shares of the Company's common stock at an exercise price of U.S.$0.10 per share and would not become exercisable until the 180th day following their issuance. Under the second pre-payment option, provided that the Company has closed a private placement of shares of its common stock for aggregate gross proceeds of at least U.S.$4,000,000, the Company may repay the Original Bridge Loan in full by issuing to the lenders shares of its common stock, in an aggregate amount equal to the amount of outstanding principal and accrued interest, at a 15% discount to the price paid by the private placement investors. Any exercise by the Company of the second pre-payment option would be subject to shareholder and regulatory approval. Should the Company exercise either of these pre-payment options, it will be obligated to pre-pay the Additional Bridge Loan in the same manner, provided that the Company, in no event, shall be obligated to issue warrants exercisable into shares in a number that exceeds 20% of the issued and outstanding shares of the Company's common stock on the date of pre-payment.

ELDORADO ARTESIAN SPRINGS INCORPORATED (OTCBB: ELDO)
"Up 37.14% on Monday"

Detailed Quote: http://www.otcpicks.com/quotes/ELDO.php

Eldorado Artesian Springs, Inc. engages in the bottling, marketing, and distribution of artesian spring water under the Eldorado Artesian Spring Water brand primarily in Colorado. It sells five gallon and three gallon bottles of water directly to home and business, retail grocery stores, and distributors located in Colorado. The company also sells its water at wholesale to retail food stores for retail distribution. In addition, it sells and rents filtration equipment and coffee dispensing equipment to customers for home and office accounts; sells coffee; and owns and operates a public swimming pool. The company was founded in 1983 and is headquartered in Louisville, Colorado.

ELDO News:

May 5 - Eldorado Artesian Springs Feature to Air Today on CNBC Power Lunch 'Mike on America' Segment

Eldorado Artesian Springs, Inc. (OTCBB: ELDO) announced that the Company is scheduled to be featured on CNBC's Power Lunch program today, May 5, 2008. The feature was done by roving business reporter Mike Hegedus for his regular "Mike on America" segment, which typically runs toward the end of the two-hour Power Lunch program. Power Lunch is scheduled to air today from 10 a.m. to 12:00 noon Mountain Time. Should the Eldorado feature not air due to breaking news or other reasons, the Company will announce the new scheduled airtime once it is available.